We posit that this finding indicates that individuals with the NAT2 slow acetylator phenotype have reduced detoxification of HAA carcinogens and increased chance of carcinogen activation, compared with other acetylator phenotypes in individuals with prostate cancer. Here, NAT2 is linked to prostate cancer.